01 Molecular Testing Is Moving Closer to the Patient The Point of Care Diagnostics Market is shifting toward compact molecular systems that bring laboratory-quality testing into clinics, urgent-care centers, and other decentralized settings. PCR-based point-of-care platforms can identify infections during the same visit, helping clinicians make treatment decisions without waiting for samples to return from centralized laboratories. New systems are also combining several pathogens in one test, increasing clinical value while reducing separate testing steps. This trend expands point-of-care diagnostics beyond traditional glucose meters and lateral-flow tests into higher-value molecular applications. It creates demand for compact analyzers, multiplex assays, automated sample processing, and connected reporting systems capable of delivering accurate results with limited laboratory infrastructure. In January 2025, Roche received U.S. FDA clearance and CLIA waivers for cobas liat STI multiplex assays that use PCR technology and provide results in about 20 minutes.
01 Faster Clinical Decisions Are Driving Near-Patient Testing Point-of-care systems shorten this pathway by generating results near the patient, allowing clinicians to connect diagnosis and treatment more closely. WHO states that point-of-care testing can improve treatment decision-making, avoid referrals, increase healthcare efficiency, and reduce costs, particularly where laboratory infrastructure is weak.
01 Regulatory Evidence Requirements Can Slow New Test Deployment Point-of-care tests must be simple to operate without sacrificing accuracy, creating a significant regulatory barrier for manufacturers. In the United States, tests are categorized according to complexity, and manufacturers seeking CLIA-waived status for applicable moderate-complexity products must provide scientifically valid evidence that statutory waiver criteria are satisfied. This means companies may need additional flex studies, clinical studies, usability evidence, and documentation after obtaining initial marketing authorization. These requirements protect patients but can increase development costs and extend commercialization timelines. The challenge is particularly important for smaller diagnostic companies that need to fund both technology development and extensive validation before accessing the broad decentralized settings where waived tests can be used.
01 Local Manufacturing Can Expand Diagnostics in Underserved Regions Local production creates a major opportunity for point-of-care diagnostics because many countries with limited laboratory infrastructure also depend heavily on imported tests. Technology transfer can help establish regional manufacturing, shorten supply chains, build technical capability, and improve preparedness for disease outbreaks. Rapid tests are especially suitable because many require little additional equipment and can be deployed in smaller health facilities. Expanding production in underserved regions could therefore create new markets for diagnostic components, manufacturing equipment, quality systems, and finished tests. The opportunity is not limited to one disease because adaptable rapid-test platforms can potentially support HIV, malaria, syphilis, and other infectious-disease programs as healthcare needs change.
01 Usability and Accessibility Must Improve as Testing Moves Outside Laboratories A major challenge is ensuring that rapid tests remain easy and reliable for people with different physical abilities, literacy levels, and testing experience. As diagnostics move from trained laboratories into clinics, pharmacies, community settings, and homes, product design becomes as important as analytical performance. Small text, confusing symbols, difficult packaging, and complicated sample-handling steps can prevent users from completing tests correctly. Addressing these requirements can increase development work, but failure to do so may restrict adoption among older adults, people with disabilities, and other populations that could benefit significantly from decentralized diagnostics.
September 2025 Danaher expanded its point-of-care diagnostics capabilities through its operating companies by advancing rapid testing platforms and diagnostic workflow solutions for healthcare providers.
July 2025 Siemens Healthineers expanded its point-of-care testing portfolio by advancing blood gas, immunoassay, and rapid diagnostic technologies to support decentralized testing environments.
June 2025 Roche expanded its point-of-care diagnostics business by strengthening near-patient testing solutions, including systems designed for faster disease detection and improved healthcare workflow efficiency.
May 2025 Abbott expanded its point-of-care diagnostics portfolio by advancing rapid testing solutions and connected diagnostic platforms, supporting faster clinical decision-making in hospitals, clinics, and decentralized healthcare settings.